Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
16.09
+0.93 (6.13%)
Jul 30, 2025, 3:52 PM - Market open
Korro Bio Employees
Korro Bio had 104 employees as of December 31, 2024. The number of employees increased by 2 or 1.96% compared to the previous year.
Employees
104
Change (1Y)
2
Growth (1Y)
1.96%
Revenue / Employee
$46,356
Profits / Employee
-$840,490
Market Cap
151.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 104 | 2 | 1.96% |
| Dec 31, 2023 | 102 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KRRO News
- 9 days ago - Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 - GlobeNewsWire
- 2 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - GlobeNewsWire
- 4 months ago - Korro Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 5 months ago - Korro to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 8 months ago - Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire